The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
about
The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The association between clinic ...... 94 cases with EGFR mutations.
@en
The association between clinic ...... ptor-tyrosine kinase inhibitor
@nl
type
label
The association between clinic ...... 94 cases with EGFR mutations.
@en
The association between clinic ...... ptor-tyrosine kinase inhibitor
@nl
prefLabel
The association between clinic ...... 94 cases with EGFR mutations.
@en
The association between clinic ...... ptor-tyrosine kinase inhibitor
@nl
P2093
P2860
P356
P1433
P1476
The association between clinic ...... 94 cases with EGFR mutations.
@en
P2093
Hai-Peng Xu
Hui-Hua Hu
Jing-Hui Lin
Qiang Wang
Zhi-Yong He
P2860
P304
P356
10.18632/ONCOTARGET.13787
P407
P577
2016-12-03T00:00:00Z